Hubei Jumpcan Pharmaceutical Co Ltd (600566.SS)
600566.SS on Shanghai Stock Exchange
40.43CNY
17 Aug 2018
40.43CNY
17 Aug 2018
Change (% chg)
¥-1.02 (-2.46%)
¥-1.02 (-2.46%)
Prev Close
¥41.45
¥41.45
Open
¥41.48
¥41.48
Day's High
¥41.85
¥41.85
Day's Low
¥40.15
¥40.15
Volume
3,819,911
3,819,911
Avg. Vol
4,708,984
4,708,984
52-wk High
¥54.97
¥54.97
52-wk Low
¥34.35
¥34.35
Revenue & Earnings Per Share
| Revenue* | Earnings Per Share** | ||
|---|---|---|---|
| FY 2018 | Jun '18 | 1,676.12 | 0.464 |
| Mar '18 | 2,127.61 | 0.574 | |
| FY 2017 | Dec '17 | 1,428.39 | 0.390 |
| Sep '17 | 1,403.45 | 0.402 | |
| Jun '17 | 1,405.36 | 0.360 | |
| Mar '17 | 1,404.81 | 0.359 | |
| FY 2016 | Dec '16 | 1,171.42 | 0.319 |
| Sep '16 | 1,152.67 | 0.292 | |
| Jun '16 | 1,197.19 | 0.292 | |
| Mar '16 | 1,156.62 | 0.268 |
*Note: Units in Millions ofRenminbi
**Note: Units in Renminbi
Consensus Estimates Analysis
| # of Estimates | Mean | High | Low | 1 Year Ago | |
|---|---|---|---|---|---|
| SALES (in millions) | |||||
| Year Ending Dec-18 | 7 | 7,155.33 | 7,387.00 | 6,919.32 | 6,988.15 |
| Year Ending Dec-19 | 7 | 8,691.12 | 9,168.26 | 8,295.43 | 8,416.23 |
| Earnings (per share) | |||||
| Year Ending Dec-18 | 7 | 1.99 | 2.08 | 1.72 | 1.89 |
| Year Ending Dec-19 | 7 | 2.49 | 2.59 | 2.14 | 2.35 |
Sales and Profit Figures in China Yuan Renminbi (CNY);
Valuation Ratios
| Company | industry | sector | ||
|---|---|---|---|---|
| P/E Ratio (TTM) | 27.73 | 30.93 | 32.76 | |
| P/E High - Last 5 Yrs. | 31.48 | 40.66 | 45.44 | |
| P/E Low - Last 5 Yrs. | 17.01 | 23.69 | 24.26 | |
| Beta | 0.47 | 0.90 | 0.89 | |
| Price to Sales (TTM) | 5.81 | 3.94 | 5.75 | |
| Price to Book (MRQ) | 8.29 | 4.88 | 5.00 | |
| Price to Tangible Book (MRQ) | 9.32 | 5.70 | 6.57 | |
| Price to Cash Flow (TTM) | -- | 22.85 | 23.29 | |
| % Owned Institutions | -- | 1.23 | 2.21 | |
Dividends
| Company | industry | sector | ||
|---|---|---|---|---|
| Dividend Yield | 1.98 | 1.57 | 1.51 | |
| Dividend Yield - 5 Year Avg | 1.74 | 1.58 | 1.52 | |
| Dividend 5 Year Growth Rate | 135.87 | 4.35 | 5.22 | |
| Payout Ratio(TTM) | 54.95 | 45.85 | 43.78 | |
Growth Rates
| Company | industry | sector | ||
|---|---|---|---|---|
| Sales (MRQ) vs Qtr. 1 Yr. Ago | 17.39 | 2.27 | 8.01 | |
| Sales (TTM) vs TTM 1 Yr. Ago | 20.84 | 4.77 | 5.64 | |
| Sales - 5 Yr. Growth Rate | 81.05 | 9.94 | 10.18 | |
| EPS (MRQ) vs Qtr. 1 Yr. Ago | 23.04 | 17.61 | 20.60 | |
| EPS (TTM) vs TTM 1 Yr. Ago | 31.02 | -- | -- | |
| EPS - 5 Yr. Growth Rate | 82.83 | 9.75 | 10.66 | |
| Capital Spending - 5 Yr. Growth Rate | 39.73 | 15.37 | 15.34 | |
Financial Strength
| Company | industry | sector | |
|---|---|---|---|
| Quick Ratio (MRQ) | 1.69 | 2.15 | 2.22 |
| Current Ratio (MRQ) | 1.84 | 2.94 | 3.03 |
| LT Debt to Equity (MRQ) | 0.00 | 10.03 | 12.51 |
| Total Debt to Equity (MRQ) | 3.15 | 14.07 | 16.85 |
| Interest Coverage (TTM) | -- | 35.77 | 32.63 |
Profitability Ratios
| Company | industry | sector | ||
|---|---|---|---|---|
| Gross Margin (TTM) | 83.25 | 54.71 | 54.37 | |
| Gross Margin - 5 Yr. Avg. | 84.42 | 52.10 | 52.17 | |
| EBITD Margin (TTM) | 23.40 | -- | -- | |
| EBITD - 5 Yr. Avg | 21.66 | 18.48 | 10.65 | |
| Operating Margin (TTM) | 23.47 | 14.31 | 4.32 | |
| Operating Margin - 5 Yr. Avg. | 19.31 | 14.43 | 6.06 | |
| Pre-Tax Margin (TTM) | 24.39 | 14.80 | 5.18 | |
| Pre-Tax Margin - 5 Yr. Avg. | 20.53 | 14.82 | 6.49 | |
| Net Profit Margin (TTM) | 20.97 | 11.05 | 1.48 | |
| Net Profit Margin - 5 Yr. Avg. | 17.58 | 11.12 | 2.77 | |
| Effective Tax Rate (TTM) | 14.03 | 23.22 | 23.11 | |
| Effective Tax Rate - 5 Yr. Avg. | 14.39 | 23.48 | 23.97 | |
Efficiency
| Company | industry | sector | ||
|---|---|---|---|---|
| Revenue/Employee (TTM) | 1,003,176 | 952,976,482 | 860,375,103 | |
| Net Income/Employee (TTM) | 210,358 | 112,117,219 | 101,207,184 | |
| Receivable Turnover (TTM) | 3.47 | 5.72 | 5.87 | |
| Inventory Turnover (TTM) | 4.77 | 2.63 | 3.41 | |
| Asset Turnover (TTM) | 1.08 | 0.96 | 0.94 | |
Management Effectiveness
| Company | industry | sector | ||
|---|---|---|---|---|
| Return on Assets (TTM) | 22.73 | 11.58 | 11.13 | |
| Return on Assets - 5 Yr. Avg. | 20.57 | 12.95 | 12.40 | |
| Return on Investment (TTM) | 31.21 | 15.07 | 14.61 | |
| Return on Investment - 5 Yr. Avg. | 30.33 | 16.90 | 16.13 | |
| Return on Equity (TTM) | 31.81 | 16.59 | 16.33 | |
| Return on Equity - 5 Yr. Avg. | 31.05 | 17.97 | 17.39 | |
| 1 Year | 3 Year | 5 Year | |
|---|---|---|---|
| Sales % | 24.15 | 24.10 | 81.05 |
| EPS (TTM) % | 33.17 | 21.07 | 82.83 |
| Dividend % | 4.29 | -- | 135.87 |
Note: Units in Millions of US Dollars
Performance for Hubei Jumpcan Pharmaceutical Co Ltd
Note:: Rank is a percentile that ranges from 0 to 99, with 99 = best.
- HK stocks hit near 1-year low as tech shares slump; China slips
- BRIEF-Hubei Jumpcan Pharmaceutical to pay cash dividend of 10 yuan per 10 shares (before tax) for 2017
- BRIEF-Hubei Jumpcan Pharmaceutical's Q1 Net Profit Up 60.6 Percent Y/Y
- BRIEF-Hubei Jumpcan Pharmaceutical's 2017 Net Profit Up 31.0 Pct Y/Y At 1.2 Bln Yuan
- BRIEF-Hubei Jumpcan Pharmaceutical unit obtains high-tech enterprise recognition and to enjoy tax preference
Institutional Holders
| % Shares Owned: | 8.69% |
| # of Holders: | 64 |
| Total Shares Held: | 70,760,947 |
| 3 Mo. Net Change: | 81,535 |
| # New Positions: | 3 |
| # Closed Positions: | 3 |
| # Increased Positions: | 6 |
| # Reduced Positions: | 5 |
| # Net Buyers: | 1 |
NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.